Pipeline
Pipeline

Pipeline

Bicycle is developing several molecules in the clinic, and advancing many additional discovery-stage projects.

Bicycles are a novel molecule formed by constraining short linear peptides into a stabilized bi-cyclic structure using a central chemical scaffold.

The resulting structure enables Bicycles to effectively mimic protein-protein interactions. Bicycles combine the pharmacological properties normally associated with a biologic with the pharmacokinetic and synthetic advantages of a small molecule.

Bicycles can be readily conjugated to other chemical payloads, or to other Bicycles:

  • Bicycle Toxin Conjugates® contain a Bicycle targeted to a specific tumor antigen, a selectively cleavable linker, and a small molecule toxin payload
  • Bicycle Radio Conjugates contain a Bicycle targeted to a specific tumor antigen, a selectively cleavable linker and a highly potent radioisotope
  • Bicycles can be designed as immune cell agonists that are guided to the tumor under the direction of a tumor antigen targeting Bicycle

Bicycle Toxin Conjugates

Preclinical
IND-Enabling
Phase 1
Phase 2 / Expansion
Phase 3
zelenectide pevedotin
BT5528
BT1718
CRUK

Bicycle Radio Conjugates

Preclinical
IND-Enabling
Phase 1
Phase 2 / Expansion
Phase 3
Select targets
DKFZ
Select targets
Novartis
Select targets
Bayer

Immuno-oncology

Preclinical
IND-Enabling
Phase 1
Phase 2 / Expansion
Phase 3
BT7480
BT7455
BT7401
CRUK
Undisclosed targets
Genentech
Expanded Access Policy
Bicycle is committed to developing innovative new medicines for patients with debilitating diseases.
Read More